PW Consulting: POCT Market to Reach USD 377.98 Million by 2032

Point-of-Care Testing (POCT) Market — Strategic Outlook for 2026

As healthcare delivery continues its decade-long shift toward decentralization, the Point-of-Care Testing (POCT) market stands out as both a growth engine and a strategic battleground for 2026. PW Consulting’s latest market study (base year 2025; forecast 2026–2032) synthesizes market-sizing, competitive positioning, regulatory dynamics, and actionable commercial playbooks designed to inform capital allocation, product roadmaps, and M&A decisions in the coming 12–18 months.
Point-of-Care Testing (POCT) Market

Why this study matters for 2026

• It translates a fast-evolving industry into clear choices: where to invest, where to partner, and where to cede ground.
• It converts macro momentum — a market that recovered from pandemic volatility to reach a substantially larger base by 2025 and is projected to grow at an 8.5% CAGR through 2032 — into tactical steps you can execute in 2026.
• It aligns commercial, regulatory and manufacturing priorities around realistic scenarios: steady adoption of decentralized diagnostics, regulatory tightening, and platform-versus-consumable economics that will determine sustainable margin pools.
• It provides executable frameworks (M&A scorecards, launch readiness, reimbursement playbooks) rather than abstract forecasts, enabling immediate use in board- and investor-level deliberations.

High-level trajectory and inflection points

The POCT market experienced notable volatility in the early 2020s, driven by episodic infectious-disease demand and supply-chain disruption. After an initial dip and recalibration, the industry expanded through 2023–2025, establishing a stronger baseline entering 2026. Our bottom-up synthesis shows an accelerating adoption curve across clinical settings, home care and acute-care triage that supports a sustained mid-single-digit to high-single-digit compound annual growth rate through the 2026–2032 forecast window.
Point-of-Care Testing (POCT) Market

Two structural inflection points shape the near-term landscape:
Point-of-Care Testing (POCT) Market

• Regulatory tightening and standardization: With the full effect of CLIA regulatory updates (implemented in early 2025), proficiency testing and defined performance bands for certain analytes have raised the bar for market entry and post-market surveillance.
• Platform economics and consumables monetization: Winners will be those who can pair rugged, reliable platforms with high-margin recurring reagents and digital services that lock in clinical workflows.

Competitive landscape — platforms, portfolios, and posture

The POCT arena is concentrated but dynamic. The top-tier vendors command meaningful scale, reflected in a moderately concentrated market (our concentration metrics show a clear leading group). These incumbents are differentiated along several axes: breadth of test menus, accuracy vs. speed trade-offs, regulatory clearances (including CLIA waivers), channel reach, and installed-base service economics.

• Abbott Laboratories — Known for rapid, high-frequency analyzers and molecular platforms that target cardiac, infectious and metabolic markers. Their strategy emphasizes integrated point-of-care workflows and strong commercial channels.
• F. Hoffmann‑La Roche Ltd — Focused on rapid molecular panels enabling multi-target diagnostics at the point of care. Recent regulatory wins have strengthened their position in ambulatory and clinic settings.
• Siemens Healthineers — Competes with extensive POCT solutions for blood gas, cardiac and routine testing; their emphasis is on interoperability with hospital information systems and throughput for acute care environments.
• Danaher Corporation — Combines molecular platforms and immunoassay capability via established brands; the company’s playbook centers on test development agility and global service networks.
• QuidelOrtho — Rapid immunoassay and lateral flow expertise, with an acquisitive posture to bring complementary POCT systems to market quickly.
• Becton, Dickinson and Company (BD) — Positioning across antigen and molecular rapid tests, with an increasing focus on regulatory transitions from emergency authorizations to permanent clearances.
• bioMérieux — Strength in rapid molecular diagnostics and automated rapid systems that serve both hospital and decentralized sites.
• Thermo Fisher Scientific — A growing presence in clinical molecular POCT, leveraging a broad diagnostics portfolio and distribution reach.

Recent vendor activity underscores dynamic competitive moves: leading manufacturers secured new regulatory clearances and CLIA approvals in 2025, another key player moved from EUA-era products to permanent market authorizations mid‑year, and strategic acquisitions are being used to accelerate capability gaps. These events are shifting product mix, channel power and clinical adoption curves.

Regulatory and product dynamics to watch in 2026

• CLIA updates that took effect in 2025 impose stricter proficiency testing and defined performance bands for several analytes — companies must demonstrate routine compliance and robust training/QA programs.
• Transitioning tests from emergency pathways to full clearances has become a commercial imperative for scale; expect sustained submission activity and a renewed focus on formal clinical validation.
• Novel rapid assays for respiratory pathogens and multiplexed panels have entered the market; these expand use cases but also raise clinical‑utility questions that payers will scrutinize.

Strategic implications for executives — the PW Consulting playbook

Below are pragmatic moves to prioritize in 2026. Each is grounded in the report’s quantitative scenarios and validated by client advisory work across the diagnostics value chain.

• Prioritize platform investments that unlock consumable annuities. Build roadmaps that balance capital-light instruments with high-margin reagent franchises.
• Design modular validation plans. Sequentially pursue CLIA waivers or equivalent local designations that expand point-of-care adoption while containing regulatory risk.
• Align channel strategies to clinical workflows. For acute-care platforms, invest in hospital service and IT integration; for ambulatory and home use, build distribution and telehealth partnerships.
• Use M&A tactically to fill capability gaps. Target acquisitions or licensing deals that accelerate multiplexing, sample-to-answer automation or connectivity features rather than chasing low-margin, standalone assays.
• Lock in payers early. Build health-economic dossiers and real-world evidence generation plans in tandem with clinical rollouts to shorten reimbursement timelines.
• Stress-test supply chains. Scenario-plan for reagent shortages, single-supplier risks and regional manufacturing contingencies to avoid revenue loss during demand spikes.
• Monetize data and services. Beyond tests and instruments, bundle analytics, quality-assurance services and teleconsultation to expand customer lifetime value.

What this PW Consulting report delivers (practical contents)

The full report is engineered for decisions, not curiosity. It includes:

• Methodology and transparent market-sizing assumptions (historical 2020–2025 and forecast 2026–2032), with scenario and sensitivity modelling tailored to varying adoption rates and reimbursement outcomes.
• Platform- and test-level competitive benchmarking and vendor scorecards, including regulatory posture, installed-base economics, and R&D pipelines.
• Commercial playbooks: go-to-market templates, pricing and reimbursement strategies, market-entry checklists, and sales-force deployment models.
• M&A heatmaps and diligence checklists highlighting logical targets by capability and geography.
• Operational readiness tools: manufacturing scale-up templates, validation timelines, and supply-chain risk matrices.
• Case studies and primary interviews with hospital labs, clinic purchasing leads and payers that illustrate adoption barriers and procurement levers.

In keeping with a “trailer” approach, this introduction intentionally omits granular segmentation tables and finer breakdowns (regional shares, application splits and product-line dollar splits) that are included exclusively in the full report. That granularity is central to transaction-level diligence and is available with the complete report package.

How to use these insights in 2026 — a one-page execution checklist

• CEO / Board: Validate portfolio against the 2026 operating plan using PW’s scenario models — prioritize cash-generative, high-consumables platforms.
• Head of R&D: Accelerate modular clinical studies aligned to CLIA-level targets; design early payer-engagement protocols for economic evidence.
• Commercial Leader: Map top 50 accounts by POCT adoption readiness and align field resources to high-return segments (acute triage, ambulatory clinics, home health partnerships).
• Head of Corporate Development: Use the M&A heatmap to shortlist targets that deliver either rapid menu expansion or critical digital/connectivity capabilities.
• Operations / Supply Chain: Implement dual-sourcing and reagent-inventory buffers for the next 24 months to mitigate demand shocks.

Concluding perspective

The POCT market presents a clear growth runway through 2032 — with substantial opportunity for well-positioned sellers to capture both device and high-margin consumable value. Regulatory tightening and a return to evidence-driven procurement mean that market access is increasingly a function of clinical, operational and commercial excellence. PW Consulting’s study converts this complex landscape into prioritized actions for 2026: invest where annuities are defensible, partner to accelerate capability gaps, and build evidence to secure durable reimbursement.

For executive teams preparing near-term budgets, M&A pipelines, or product launches, our full report provides the granular segmentation, scenario outputs and playbooks required to de-risk decisions and capture a disproportionate share of upside. PW Consulting can also deliver tailored workshops to convert the report insights into a 90-day execution plan aligned to your organization’s objectives.

For detailed analysis of this topic, please visit the official page: Point-of-Care Testing (POCT) Market

Lacy Lee
Senior Marketing Manager
sales@pmarketresearch.com
00852-95632430
PW Consulting: www.pmarketresearch.com